Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

被引：0
|
作者：
Hallek, M. [1 ]
Hillmen, P. [2 ]
Furman, R. R. [3 ]
Coutre, S. E. [4 ]
Sharman, J. P. [5 ]
Pagel, J. M. [6 ]
Barrientos, J. C. [7 ]
Zelenetz, A. D. [8 ]
Kipps, T. J. [9 ]
Flinn, I. W. [10 ]
Ghia, P. [11 ]
Eradat, H. [12 ]
Erwin, T. [13 ]
Lamanna, N. [14 ]
Coiffier, B. [15 ]
Pettitt, A. R. [16 ]
O'Brien, S. M. [17 ]
Cheson, B. D. [18 ]
Ruppert, S. [19 ]
Kroenig, H. [19 ]
Schuster, A. [19 ]
机构：
[1] Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Weill Cornell Med Coll, New York, NY USA
[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] US Oncol Res, Springfield, OR USA
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[7] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Univ Vita Salute San Raffaele, Ist Sci San Raffaele, Milan, Italy
[12] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[13] Florida Canc Specialists, Englewood, CO USA
[14] Columbia Univ, Med Ctr, New York, NY USA
[15] Lyon Sud Univ Hosp, Lyon, France
[16] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[18] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[19] Gilead Sci GmbH, Martinsried, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P191
引用
收藏
页码：52 / 53
页数：2
相关论文
共 50 条
  • [31] A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma
    Daisuke Tsutsumi
    Tatsuya Hayama
    Katsuhiro Miura
    Akihiro Uchiike
    Shinya Tsuboi
    Susumu Otsuka
    Yoshihiro Hatta
    Yukinaga Kishikawa
    International Journal of Clinical Pharmacy, 2022, 44 : 366 - 373
  • [32] Daratumumab/Eltrombopag/Rituximab Acute infusion-related reactions, off label use and lack of efficacy
    Reactions Weekly, 2024, 2014 (1) : 211 - 211
  • [33] Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
    Jocelyn Courville
    Loretta Nastoupil
    Nitin Kaila
    John Kelton
    Jeffrey Zhang
    Ann Alcasid
    Pilar Nava-Parada
    BioDrugs, 2021, 35 : 459 - 468
  • [34] Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
    Courville, Jocelyn
    Nastoupil, Loretta
    Kaila, Nitin
    Kelton, John
    Zhang, Jeffrey
    Alcasid, Ann
    Nava-Parada, Pilar
    BIODRUGS, 2021, 35 (04) : 459 - 468
  • [35] Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease
    Rusch, Caroline
    Wood, Marci
    Kennedy, Amanda G.
    Tompkins, Bradley J.
    Frasca, Joseph D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1851 - 1857
  • [36] Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
    Park, Keunchil
    Sabari, Joshua
    Haura, Eric B.
    Shu, Catherine A.
    Spira, Alexander
    Salgia, Ravi
    Reckamp, Karen L.
    Sanborn, Rachel E.
    Govindan, Ramaswamy
    Bauml, Joshua M.
    Curtin, Joshua C.
    Xie, John
    Roshak, Amy
    Lorenzini, Patricia
    Millington, Dawn
    Thayu, Meena
    Knoblauch, Roland E.
    Cho, Byoung Chul
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S482
  • [37] Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
    Loirat, Delphine
    Logeart, Juliette
    Vaflard, Pauline
    Noret, Aurelien
    Saint-Ghislain, Mathilde
    Borcoman, Edith
    Hurgon, Audrey
    Cros, Cyrille
    Genevee, Thomas
    Bellesoeur, Audrey
    Ricci, Francesco
    Lerebours, Florence
    Escalup, Laurence
    Sablin, Marie-Paule
    Bidard, Francois-Clement
    Cottu, Paul H.
    Pierga, Jean-Yves
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
    Richard Greil
    Alessandra Tedeschi
    Carol Moreno
    Bertrand Anz
    Loree Larratt
    Martin Simkovic
    Devinder Gill
    John G. Gribben
    Ian W. Flinn
    Zhengyuan Wang
    Leo W. K. Cheung
    Aaron N. Nguyen
    Cathy Zhou
    Lori Styles
    Fatih Demirkan
    Annals of Hematology, 2021, 100 : 1733 - 1742
  • [39] Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
    Greil, Richard
    Tedeschi, Alessandra
    Moreno, Carol
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Gill, Devinder
    Gribben, John G.
    Flinn, Ian W.
    Wang, Zhengyuan
    Cheung, Leo W. K.
    Nguyen, Aaron N.
    Zhou, Cathy
    Styles, Lori
    Demirkan, Fatih
    ANNALS OF HEMATOLOGY, 2021, 100 (07) : 1733 - 1742
  • [40] SEVERE INFUSION-RELATED REACTIONS ARE UNCOMMON IN RITUXUMAB-TREATED CLL PATIENTS: RESULTS FROM A NATIONAL OBSERVATIONAL STUDY
    Norin, N.
    Bjorkstrand, B.
    Rommel, F.
    Timberg, L.
    Andersson, P.
    Haggstrom, J.
    Aldrin, A.
    Hansson, L.
    HAEMATOLOGICA, 2012, 97 : 306 - 306
12345